If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGcp Asset Bckd Regulatory News (GABI)

Share Price Information for Gcp Asset Bckd (GABI)

Share Price is delayed by 15 minutes
Get Live Data
65.40    0.00 (0.00%)
Bid:
64.00
Ask:
66.80
Spread: 2.80 (4.375%)
Market Cap: £112.42m
GABI Live PriceLast checked at - London Stock Exchange

Intraday Gcp Asset Bckd Share Chart

Quarterly Update

26 Jul 2024 07:00

RNS Number : 8461X
GCP Asset Backed Income Fund Ltd
26 July 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

FOR IMMEDIATE RELEASE

26 July 2024

GCP Asset Backed Income Fund Limited

("GABI" or the "Company")

LEI: 213800FBBZCQMP73A815

Quarterly Update

GCP Asset Backed, which invested in asset backed loans, announces that, at 30 June 2024, the unaudited net asset value ("NAV") per ordinary share of the Company (including current period revenue) is 90.92 pence per share.

NAV

The NAV represents a quarterly decrease of 0.33 pence per ordinary share (0.36%) from 31 March 2024. This decrease primarily reflects asset-specific revaluations, including loan-specific impairments and discount rate movements. The weighted average discount rate of the portfolio at 30 June 2024 was 10.37%, a decrease of 0.32 percentage points over the quarter (largely resulting from the evolution of the underlying portfolio as a result of the repayments received) and an increase of 1.07 percentage points since 30 June 2023.

Capital allocation

During the quarter ending 30 June 2024, the Company did not make any investments. As of 30 June 2024, the revolving credit facility ("RCF") commitments were reduced to £1 million to lower ongoing financing costs, primarily commitment fees, ahead of the RCF's maturity in August 2024. The reduced facility has been retained for use in relation to the Company's FX hedging contracts. Cash on hand as of 30 June 2024 was £5.6 million.

The initial capital distribution, as declared on 3 June 2024 was made on 24 June 2024. On a pro rata basis, 159,609,669 ordinary shares, representing approximately 37.5% of the Company's issued shares, were compulsorily redeemed at 89.66875 pence per share as of 10 June 2024. Following this redemption, the Company has 266,016,390 ordinary shares in issue.

No new investment activity is planned for the current quarter. The focus remains on the orderly realisation of the portfolio and the active management of the portfolio by the Investment Manager, aiming to accelerate redemptions or disposals where possible, in line with the Investment Manager's published realisation plan (the "Realisation Plan").

Portfolio update

In determining the 30 June 2024 valuations, Mazars, the Company's independent valuation agent, has applied certain asset-specific discount rate adjustments or impairments to reflect updates to loan and/or borrower performance during the period. During the period, £87.7 million in repayments were received, reducing the number of total loans outstanding from 39 to 31. As announced by the Company on the 8 July 2024, an additional repayment of £10.1m was received after the 30 June 2024, reducing total outstanding facilities to £244.4 million. Additionally, £7.8 million of interest was realised over the period.

Two assets were removed from the Watchlist or Problem Loans list during the quarter, with six loans classified as either Problem or Watchlist loans as of quarter-end. The Company and Investment Manager continue to work to resolve the remaining Problem and Watchlist loans. More details on the status of these loans is provided below:

Watchlist and Problem Loans (representing 11.6% of the 30 June 2024 NAV):

· Co-living group (0.0% NAV): This asset has been written down to nil (0.32% of the NAV at 31 March 2024) due to increased uncertainty on eventual recovery. Though recovery is still possible, the Investment Manager and Mazars believe the degree of uncertainty and limited control over the recovery process warrant a full impairment of the remaining facility. This is also in line with the recovery estimates set out in the Realisation Plan.

· Social housing (4.3% NAV): Classified as a Problem Loan due to persistent covenant breaches and failure to meet repayment obligations related to wider financial and regulatory challenges at one of the registered providers. The Investment Manager is progressing the early realisation of this investment in accordance with the Realisation Plan.

· Multi-use community facilities (0.3% NAV): The Investment Manager is in discussions to exit the position and is actively exploring a number of options.

· Student accommodation (0.5% NAV): The borrower has requested an extension to facilitate the refinancing or sale of the asset to repay the loan. Following the end of the reporting period, a positive planning decision was received regarding the property, which is expected to significantly increase the collateral value. This position will be reassessed in the second half of the year. The Investment Manager continues to work with the borrower to achieve an exit through sale, refinance, or redemption.

· Multi-use community facilities (0.9% NAV): Continued performance improvements have been seen, and the asset continues to make payments linked to turnover, in line with contractual requirements. The borrower has provided an updated long-term budget for the project during the period resulting in a further impairment of the facility. The position will continue to be monitored and the loan remains on the Watchlist until further improvement is established.

· Co-living (5.6% NAV): As previously communicated in the Company's 2023 annual report and accounts, this facility has been classified as a Watchlist loan due to the receipt by the Investment Manager of an updated valuation showing a breach of the facility's LTV covenant, and the borrower's failure to meet cash interest payments after the facility fell outside its contractual interest capitalisation period. The Investment Manager continues to engage with the borrower, who has made significant progress in stabilising the asset, noting consistently high occupancy levels and a key commercial tenant expected to take residence. This is expected to positively affect valuation and improve the LTV position. Discussions on a redemption of the facility are ongoing.

Further details will be provided in the Company's forthcoming interim accounts.

Dividends

On 25 April 2024, the Directors declared a quarterly dividend for the period from 1 January 2024 to 31 March 2024 of 1.58125p per share, which was paid on 4 June 2024. Aggregate dividend payments over the last 12 months represent a 8.3% yield on the Company's closing share price at 18 July 2024.

For further information:

GCP Asset Backed Income Fund Limited

Alex Ohlsson, Chairman

+44 (0)15 3482 2251

Gravis Capital Management Limited - Investment Manager

Philip Kent

Anthony Curl

Cameron Gardner

+44 (0)20 3405 8500

Barclays Bank PLC, acting through its Investment Bank - Corporate Broker

Dion Di Miceli

Stuart Muress

James Atkinson

 

+44 (0) 20 7623 2323

BarclaysInvestmentCompanies@barclays.com

Buchanan/Quill - Media Enquiries

Helen Tarbet

Henry Wilson

George Beale

 

+44 (0)20 7466 5000

Notes to the Editor

About GABI

GCP Asset Backed Income Fund Limited is a closed ended investment company. Its shares are traded on the Premium Segment of the Main Market of the London Stock Exchange. Its investment objective is to undertake a managed wind-down of the Company and realise all existing assets in the Company's portfolio in an orderly manner.

The Company's portfolio comprises a diversified portfolio of predominantly UK based asset backed loans which are secured against contracted, predictable medium to long term cash flows and/or physical assets.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUGCGDRUDDDGSU
Date   Source Headline
24th Jul 20197:00 amRNSDividend Declaration & Scrip Dividend Alternative
16th Jul 20197:00 amRNSNet Asset Value(s)
1st Jul 20194:04 pmRNSChange of Name Administrator and Company Secretary
28th Jun 20197:00 amRNSTotal Voting Rights
27th Jun 201911:47 amRNSHolding(s) in Company
25th Jun 20198:39 amRNSResult of Placing
13th Jun 20194:14 pmRNSNew Directorship Notification
4th Jun 20199:26 amRNSTotal Voting Rights & Additional Listing
24th May 20197:00 amRNSAdditional Listing
23rd May 20191:39 pmRNSProposed Placing of New Ordinary Shares
23rd May 20191:30 pmRNSResult of AGM & EGM
10th May 20192:06 pmRNSScrip Share Reference Price - Replacement
10th May 201912:17 pmRNSScrip Share Reference Price
1st May 20197:00 amRNSInvestor Report as at 31 March 2019
25th Apr 20194:11 pmRNSHolding(s) in Company
24th Apr 20197:00 amRNSDividend Declaration & Scrip Dividend Alternative
16th Apr 20197:00 amRNSRevolving Credit Facility
11th Apr 20197:00 amRNSNet Asset Value(s)
10th Apr 20197:00 amRNSNotices of AGM & EGM
29th Mar 20197:00 amRNSAnnual Report & Financial Statements
29th Mar 20197:00 amRNSTotal Voting Rights
15th Mar 20192:57 pmRNSHolding(s) in Company
1st Mar 20199:55 amRNSTotal Voting Rights and Additional Listing
21st Feb 20197:00 amRNSAdditional Listing
7th Feb 20197:00 amRNSScrip Share Reference Price
31st Jan 20197:00 amRNSInvestor Report as at 31 December 2018
29th Jan 20193:54 pmRNSDirector/PDMR Shareholding
23rd Jan 20197:00 amRNSDividend Declaration & Scrip Dividend Alternative
23rd Jan 20197:00 amRNSPossible Equity Raise
17th Jan 20194:54 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSNet Asset Value(s)
31st Dec 20187:00 amRNSTotal Voting Rights
20th Dec 20187:00 amRNSConversion of C Shares
11th Dec 20187:00 amRNSResult of Placing
5th Dec 20187:00 amRNSProposed Placing of Ordinary Shares
30th Nov 20189:25 amRNSTotal Voting Rights & Additional Listing
28th Nov 20187:00 amRNSConversion of C Shares
21st Nov 20187:00 amRNSAdditional Listing
8th Nov 20187:00 amRNSScrip Share Reference Price
1st Nov 20187:00 amRNSInvestor Report as at 30 September 2018
31st Oct 20187:00 amRNSTotal Voting Rights
23rd Oct 20187:00 amRNSDividend Declaration & Scrip Dividend Alternative
15th Oct 20187:00 amRNSNet Asset Value(s)
10th Oct 20182:42 pmRNSTotal Voting Rights
2nd Oct 20183:50 pmRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSResult of OO, Placing and OFS
28th Sep 20187:00 amRNSTotal Voting Rights
7th Sep 20181:13 pmRNSC Share Issue and publication of prospectus
5th Sep 20187:00 amRNSHalf-year Report & Financial Statements
3rd Sep 20189:00 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.